JALMARTI
LIVE

Serial Number

98502296

Owner

Novartis AG

Attorney

Maury M. Tepper, III

Filing Date

Apr 16, 2024

Add to watchlist:

No watchlists yet
View on USPTO

JALMARTI Trademark

Serial Number: 98502296

JALMARTI is a trademark filed by Novartis AG on April 16, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Novartis AG (13 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

April 16, 2024

Registration Date

Not Registered

Published for Opposition

April 1, 2025

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 26, 2026 EXRA
SOU EXTENSION 2 GRANTED
May 25, 2026 EX2G
SOU EXTENSION 2 FILED
May 25, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
May 25, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 23, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 22, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 22, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 22, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 27, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 1, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 1, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 5, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 6, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 6, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 26, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 16, 2024 NWOS
NEW APPLICATION ENTERED
Apr 16, 2024 NWAP